...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Neurology >Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis
【24h】

Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis

机译：双对急性无氧栓塞缺血性卒中或短暂性缺血攻击，疗效和安全分析 - 更新了荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

New evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention have been realized in the recent years. An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding. PubMed, Cochrane and Science Direct data bases were utilized, RCTs evaluating dual antiplatelet vs mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack within ?72?h from ictus were searched up to July 2019. Risk ratio at 95% confidence intervals were calculated to evaluate stroke recurrence, cardiac events and mortality, and major bleeding. Sixteen randomized controlled trials with a population of 28, 032 patients were pooled into a meta-analysis. Dual antiplatelet therapy was significantly superior over mono antiplatelet therapy in the reduction of stroke (RR 0.75, 95% CI:0.68–0.83, p value?0.00001) and composite events namely cardiovascular morbidity and mortality (0.73 95% CI: 0.65–0.82, p value ?0.00001), while bleeding events were noted to be not significant (1.22 95% CI: 0.87–1.70, p value?=?0.25). In acute non-cardioembolic ischemic strokes or those who have suffered a transient ischemic attack, dual antiplatelet therapy was associated with efficacy in stroke recurrence and composite cardiac events, with a non-significant risk of major bleeding.
机译：近年来，已经实现了对次级中风预防预防次级中风预防疗效和安全性的新证据。完成了更新的荟萃分析以确定各种双抗敷液与阿司匹林单独对缺血性卒中，心血管发病率和死亡率的复发率的影响，以及通过重大出血所报道的安全性。利用了PubMed，Cochrane和科学直接数据碱基，RCT评估双抗血小板对急性缺血性卒中或瞬时缺血性攻击中的急性缺血性卒中或来自ICTU的瞬时缺血性发作的速度达到2019年7月。95％置信区间的风险比率为95％计算以评估中风复发，心脏事件和死亡率，以及重大出血。汇集了16例随机对照试验，将032名患者合并到META分析中。在减少中风（RR 0.75,95％Ci：0.68-0.83，P值<0.00001）和复合事件时，双抗血小板治疗在单次抗血小板疗法中显着优异优异，P值<0.00001），同时出血事件被指出不显着（1.22 95％CI：0.87-1.70，P值？=？0.25）。在急性非心脏透明缺血性中风或患有短暂性缺血性攻击的人中，双抗血小板治疗与中风复发和复合心脏事件的功效有关，具有重要风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号